Eagle Pharmaceuticals (EGRX) Initiates $50M Accelerated Share Buyback as Part of New $150M Share Buyback Authorization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
November 1, 2018 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.
While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More
Eagle Pharmaceuticals (EGRX) Reports Prelim. 3Q EPS Above Consenus, Prelim. 3Q Revenues Below Consensus
October 30, 2018 7:34 AM EDTEagle Pharmaceuticals, Inc. (NASDAQ: EGRX) today provided preliminary financial results and announced that its Board of Directors has approved a new stock repurchase program providing for the repurchase of up to an aggregate of $150 million of Eagles common stock, consisting of (i) up to $50 million in repurchases pursuant to an accelerated... More

